Dylann Cohn-Emery

“ENZAMET adds to the body of knowledge from several other pivotal trials and now informs best practices for mHSPC,” said Ian D. Davis, MBBS, PhD, FRACP, FAChPM.

Patients in the study had tumors that were not completely resectable.

The neoadjuvant combination of the PD-1 inhibitor tislelizumab and nab-paclitaxel induced a high rate of pathologic complete response in patients with muscle-invasive bladder cancer.

The final overall survival analysis from the phase 3 CheckMate 9ER trial continued to show a benefit with frontline nivolumab/cabozantinib versus sunitinib in patients with advanced renal cell carcinoma.

The findings come from an exploratory subgroup analysis of the pivotal CheckMate 9-ER trial shared during the 2021 ESMO Congress.

The FDA is scheduled to decide on a new drug application for tivozanib by March 31, 2021, for use in relapsed/refractory renal cell carcinoma.